Unresectable gastric carcinoma
Clinical trials for Unresectable gastric carcinoma explained in plain language.
Never miss a new study
Get alerted when new Unresectable gastric carcinoma trials appear
Sign up with your email to follow new studies for Unresectable gastric carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug trio takes aim at HER2-Positive stomach cancer
Disease control Recruiting nowResearchers are comparing a new combination of disitamab vedotin, sintilimab, and S-1 against the standard regimen of trastuzumab plus chemotherapy, with or without sintilimab, for people with advanced HER2-positive gastric or gastroesophageal junction cancer. The trial enrolls a…
Matched conditions: UNRESECTABLE GASTRIC CARCINOMA
Phase 2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo aims to outsmart HER2-Positive cancers
Disease control Recruiting nowThis early-stage study tests a combination of two drugs—trastuzumab deruxtecan and azenosertib—in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and check for…
Matched conditions: UNRESECTABLE GASTRIC CARCINOMA
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC